Valued at over $1B, Ginkgo Bioworks has experienced incredible traction in the years following MassChallenge. In 2010, they were accepted into our first-ever Boston cohort, where they had an opportunity to access a global community of experts, corporates, investors, and more – all at zero cost and for zero equity. With ecosystem-wide validation and support, Ginkgo was able to turn their idea into a reality and bring their solution to the people and industries that need it most. With $275M in new funding, Ginkgo has become the first MassChallenge unicorn and one of the most-promising biotech organizations in the country.